Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,467,700 | 812,700 | 535,203 | 809,102 | 648,719 |
| Marketable Securities | 1,342,200 | 596,800 | 503,481 | 236,121 | 251,761 |
| Receivables | 2,243,200 | 1,974,300 | 1,611,620 | 1,467,793 | 976,372 |
| Inventories | 1,151,200 | 726,100 | 399,356 | 238,578 | 128,861 |
| TOTAL | $6,447,600 | $4,335,000 | $3,180,188 | $2,915,095 | $2,084,759 |
| Non-Current Assets | |||||
| PPE Net | 2,575,800 | 2,358,600 | 2,083,421 | 1,594,120 | 974,309 |
| Investments And Advances | 1,755,000 | 1,486,500 | 864,260 | 632,162 | 460,154 |
| Other Non-Current Assets | 956,100 | 584,200 | 845,597 | 467,755 | 318,450 |
| TOTAL | $5,286,900 | $4,429,300 | $3,793,278 | $2,694,037 | $1,752,913 |
| Total Assets | $11,734,500 | $8,764,300 | $6,973,466 | $5,609,132 | $3,837,672 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 218,200 | 178,200 | 879,096 | 644,112 | 483,489 |
| Other current liabilities | 772,100 | 637,200 | 1,178 | 13,563 | 97,146 |
| TOTAL | $1,442,800 | $1,135,500 | $1,241,495 | $811,162 | $654,660 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 452,500 | 320,100 | 231,664 | 153,487 | 74,025 |
| Other Non-Current Liabilities | 361,700 | 152,000 | 100,385 | 115,535 | 186,574 |
| TOTAL | $1,534,400 | $1,484,700 | $1,282,726 | $1,143,133 | $632,761 |
| Total Liabilities | $2,977,200 | $2,620,200 | $2,524,221 | $1,954,295 | $1,287,421 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 109,277 | 107,697 | 106,081 | 104,788 | 102,617 |
| Common Shares | 100 | 100 | 110 | 108 | 104 |
| Retained earnings | 5,254,300 | 2,946,700 | 1,748,222 | 852,700 | 216,644 |
| Other shareholders' equity | -12,700 | 400 | -13,080 | 8,503 | 52,721 |
| TOTAL | $8,757,300 | $6,144,100 | $4,449,245 | $3,654,837 | $2,550,251 |
| Total Liabilities And Equity | $11,734,500 | $8,764,300 | $6,973,466 | $5,609,132 | $3,837,672 |